Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038178 · ClinicalTrials.gov registry record · Phase 2
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
A Phase 2 study, sponsored by Kevin Winthrop.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03038178 is a Phase 2 study that has completed, run by Kevin Winthrop. The registered enrollment target is 30 participants.
The verdict
NCT03038178, a Phase 2 study, has completed, sponsored by Kevin Winthrop.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The proposed study will assess the efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines, for treatment of mycobacterium abscessus lung disease.
Interventions
- DRUG LAI plus multi-drug regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038178
The ClinicalTrials.gov registry entry for NCT03038178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kevin Winthrop, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LAI plus multi-drug regimen is the first listed.
NCT03038178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03038178 about?
NCT03038178 is a clinical study titled "Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease". The proposed study will assess the efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines, for treatment of mycobacterium absc...
What is the current status of trial NCT03038178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-10. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03038178?
The interventions under investigation include: LAI plus multi-drug regimen (DRUG).
Who is sponsoring clinical trial NCT03038178?
This trial is sponsored by Kevin Winthrop, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.